| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_45a3703d03a4b21be619937f5ad63b8b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
| filingDate |
2010-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3154e8f566dcd07cf333c139ad598894
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dac983f31b927a4edc540429bacbbd70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_771d9b922b4f4df33506dafda8abd75a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cfb50ad8f5be12302c717adc18faadea |
| publicationDate |
2012-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2437771-A2 |
| titleOfInvention |
Compositions and methods modulating mg29 for the treatment of diabetes |
| abstract |
Disclosed herein are compositions and methods for treatment of muscle dysfunction, including diabetes. In addition, the invention relates to therapeutic compositions comprising nucleotides and/or polypeptides of the invention in combination with a pharmaceutically acceptable carrier, wherein the composition facilitates the treatment of skeletal musle disorders. Moreover, the invention relates to the treatment and/or prevention of pathological conditions associated with altered intracellular Ca2+ reulgation and disrupted membrane structure that occurs when the expression levels of MG29 are reduced. |
| priorityDate |
2009-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |